Strattera vs Adderall in Patients with Anxiety
Anxiety and Attention Deficit Hyperactivity Disorder (ADHD) often coexist, creating unique challenges for diagnosis and treatment. Among the many medications available for managing ADHD, Strattera (atomoxetine) and Adderall (a combination of amphetamine salts) stand out as two of the most commonly prescribed. However, the choice between them becomes more nuanced when anxiety is also present. Both medications have different mechanisms of action and impact on anxiety, making the selection process critical for effective treatment. In this blog, we will explore the key differences between Strattera vs adderall, especially in the context of patients dealing with comorbid anxiety.
When it comes to managing depression and anxiety, many patients are prescribed selective serotonin reuptake inhibitors (SSRIs). Two widely used options are lexapro vs zoloft. While both medications work by increasing serotonin levels in the brain, they have distinct differences. Lexapro, often considered milder, is typically prescribed for generalized anxiety and depression, while Zoloft is often favored for a broader range of conditions, including panic disorders and PTSD. Lexapro vs Zoloft: the choice between them often depends on the patient's specific symptoms, side effects, and response to the medication. Your doctor can help guide the best choice.
Strattera, or atomoxetine, is a non-stimulant medication approved by the FDA for the treatment of ADHD. It works by selectively inhibiting the reuptake of norepinephrine, thereby increasing its levels in the brain. Unlike stimulants, Strattera is not considered a controlled substance and is not associated with the same potential for abuse or dependency. It is typically taken once or twice daily, with effects building up over several weeks. Because it doesn't produce the immediate 'boost' that stimulants provide, its impact on focus and attention is generally subtler and more gradual.
Adderall is a central nervous system stimulant composed of amphetamine salts. It increases the levels of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release. This dual action provides a powerful and rapid improvement in attention, focus, and impulse control, often noticeable within 30 to 60 minutes. However, it also comes with a higher risk for side effects like increased heart rate, elevated blood pressure, and sleep disturbances. Adderall is a Schedule II controlled substance due to its high potential for abuse and dependence.
Studies show that up to 50% of individuals with ADHD also suffer from an anxiety disorder. This comorbidity complicates treatment because stimulant medications like Adderall can sometimes exacerbate anxiety symptoms. For patients already prone to nervousness, restlessness, or panic attacks, stimulants may increase these symptoms, even while improving focus. On the other hand, untreated ADHD can contribute to increased anxiety due to struggles with productivity, forgetfulness, and organizational challenges. Therefore, choosing the right medication involves balancing the need for improved attention with the potential impact on anxiety.
One of the biggest advantages of Strattera for patients with comorbid anxiety is its generally favorable profile in terms of anxiety symptoms. Because it doesn't stimulate dopamine release in the same way as Adderall, it is less likely to cause jitteriness or exacerbate anxiety. In some cases, patients report a reduction in anxiety after starting Strattera, potentially due to improved executive function and less chaotic thinking. Furthermore, since Strattera is taken consistently and builds up gradually, it provides a more stable therapeutic effect without the peaks and valleys associated with stimulant medications.
Adderall is effective at reducing core ADHD symptoms but can be problematic for individuals with anxiety. The increased release of dopamine and norepinephrine often results in heightened alertness, which may feel similar to or even trigger anxiety in sensitive individuals. Some patients describe experiencing a racing heart, increased blood pressure, or a sense of unease while on Adderall. However, this is not universally true—some people with anxiety and ADHD respond very well to Adderall, especially if their anxiety is more situational or stems from poor ADHD control. The key factor is individual variability, and close monitoring is essential.
When choosing between Strattera and Adderall for a patient with both ADHD and anxiety, clinicians weigh several factors. Strattera is often the first-line treatment when anxiety is a major concern, especially in children and adolescents. It avoids the risk of stimulant-induced anxiety and is easier to manage long-term from a regulatory and compliance perspective. However, its slower onset of action may frustrate patients looking for quick symptom relief.
Adderall might still be chosen if the ADHD symptoms are particularly severe and impairing, and if anxiety is well-controlled through other means such as therapy or additional medication. It's also sometimes used as a trial treatment to gauge a patient's tolerance to stimulants, with the understanding that side effects like increased anxiety might necessitate a switch to a non-stimulant.
Strattera's once-daily dosing and non-stimulant nature make it convenient and low-risk for patients concerned about addiction. However, some users report side effects such as fatigue, dizziness, dry mouth, and gastrointestinal discomfort. Moreover, because it can take several weeks to become effective, patients must be patient and committed to the treatment plan.
Adderall's immediate efficacy is often appealing to patients seeking fast results. Many report feeling more 'awake,' focused, and motivated shortly after taking it. However, it requires careful timing to avoid insomnia and might lead to rebound effects when the medication wears off. Patients who are prone to anxiety attacks may find these fluctuations destabilizing.
In some cases, doctors may consider using both medications strategically or combining them with anti-anxiety treatments. For example, a patient might take a low dose of Adderall for academic or work performance, paired with an SSRI or CBT (Cognitive Behavioral Therapy) to manage anxiety. Alternatively, non-medication strategies such as mindfulness, structured routines, and exercise can enhance the effectiveness of either medication while reducing anxiety symptoms. The most successful treatment plans are usually those that are individualized and comprehensive.
Choosing between Strattera and Adderall for patients with ADHD and anxiety requires a nuanced approach. Strattera offers a non-stimulant alternative that is generally well-tolerated by anxious individuals, while Adderall delivers potent symptom relief but carries a higher risk of aggravating anxiety. The decision should be made based on a thorough clinical evaluation, patient preferences, and ongoing monitoring. Ultimately, the goal is not just to reduce ADHD symptoms, but also to support emotional well-being, reduce anxiety, and improve overall quality of life. Collaboration between patient and provider is essential to find the right balance, and often, a bit of trial and error leads to the best outcomes.
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
3 hours ago
- Associated Press
IBN Coverage: HeartBeam (NASDAQ: BEAT) Earns FDA Clearance for First Cable-Free ECG System for Arrhythmia Detection
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 20, 2025 ( NEWMEDIAWIRE ) - HeartBeam (NASDAQ: BEAT) announced it has received FDA 510(k) clearance for its flagship ECG system, a first-of-its-kind, credit card-sized, cable-free device designed to deliver high-fidelity, three-directional cardiac recordings for arrhythmia evaluation. The clearance marks a major regulatory milestone and accelerates HeartBeam's plans to improve access to timely, remote cardiac care. When symptoms arise, patients use the app-guided system to record a 30-second ECG, which is automatically uploaded to the cloud for physician review in the context of medical history. The company will soon launch an Early Access Program to engage early adopters and providers ahead of broader commercialization. This foundational clearance also sets the stage for future advancements, including 12-lead ECG synthesis, AI-based arrhythmia detection, and remote heart attack risk scoring. HeartBeam's long-term vision is to revolutionize cardiac care by enabling continuous, predictive insights outside traditional clinical settings. To view the full press release, visit About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care - all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: The latest news and updates relating to BEAT are available in the company's newsroom at Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. About IBN IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients. IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Media Contact IBN Los Angeles, California 310.299.1717 Office [email protected]
Yahoo
5 hours ago
- Yahoo
Little Remedies honey cough syrup recalled nationwide: What parents need to know
As parents, we do everything we can to keep our children safe—especially when they're sick. That's why a new nationwide recall of a popular over-the-counter children's cough medicine is raising serious concern. Medtech Products Inc. has voluntarily recalled several lots of Little Remedies® Honey Cough Syrup after the U.S. Food and Drug Administration (FDA) found the presence of Bacillus cereus, a harmful bacteria that can cause foodborne illness—and in severe cases, even death. The recalled syrup, a go-to for many parents looking for natural relief for their child's cough, was sold online and in stores across the U.S. between December 2022 and June 2025. While no serious injuries have been reported as of now, the company is urging families to stop using the affected products immediately. Here's what you need to know to keep your little ones safe. The recall affects Little Remedies® Honey Cough Syrup, sold in 4 FL OZ (118 mL) amber bottles, commonly found in pharmacies, grocery stores, and online retailers. The syrup is marketed as a gentle, natural remedy made with honey to soothe coughs in children — but the recent discovery of Bacillus cereus contamination has made certain lots unsafe for use. According to the official FDA notice, the bacteria was detected in certain lots, prompting a recall due to concerns about shelf stability and potential health risks. While no other Little Remedies® products are affected, all lots of this particular syrup still within the expiration date have been included in the recall out of an abundance of caution. Here are the affected lot numbers and expiration dates: Lot 0039 – Expires 11/2025 Lot 0545 – Expires 01/2026 Lot 0640 – Expires 02/2026 Lot 0450 – Expires 05/2026 Lot 1198 – Expires 12/2026 Each recalled bottle has a UPC of 7-56184-10737-9 and should have the lot number printed on both the label and the bottom of the box. If you have one of these in your medicine cabinet, read on for what steps to take next. Bacillus cereus is a type of bacteria that can cause foodborne illness when ingested — especially when it grows in products that are no longer shelf-stable. While it may sound unfamiliar to many parents, the symptoms it causes are unfortunately very recognizable. There are two common types of illness linked to B. cereus: The first appears 1 to 6 hours after exposure and typically causes nausea, vomiting, and stomach cramps. The second appears 8 to 16 hours after exposure, with symptoms including diarrhea and abdominal pain. In some cases, the diarrhea may be severe and watery. In most healthy children, these symptoms may pass on their own. However, exposure to high levels of can lead to more serious illness — and in rare cases, it can be fatal. If your child has consumed the recalled syrup and shows any of these symptoms, it's important to contact your pediatrician or seek medical attention right away. When in doubt, trust your instincts — you know your child best. Related: Here's how I'm preparing for my kids' sick days this year If you have a bottle of Little Remedies® Honey Cough Syrup at home, the first step is to stop using it immediately — even if your child has taken it without any symptoms. Check both the UPC (7-56184-10737-9) and the lot number, which can be found on the bottle label and the bottom of the box. Here's what to do next: If your child has taken the syrup and is experiencing nausea, vomiting, diarrhea, or stomach pain, call your pediatrician right away. If your child seems fine, monitor them closely for symptoms for up to 24 hours. To request a refund or report an issue, you can contact Medtech directly: Call: (800) 754-8853 (Monday–Friday, 8:30 a.m. to 5:30 p.m. ET) Email: medicalaffairs@ Website: If you or your healthcare provider believe your child experienced a reaction to the product, you can also report it through the FDA's MedWatch program at It's always okay to ask questions, trust your instincts, and reach out for guidance when your child's health is involved. Related: Target recalls baby food over lead concerns—here's what parents should do Recalls like this can feel unsettling, especially when they involve products we trust. But by staying informed and taking quick action, you're doing exactly what your child needs. No serious injuries have been reported, and the recall is precautionary — but it's always better to be safe. If you have concerns, talk to your pediatrician. When it comes to your child's health, caution is care.
Yahoo
5 hours ago
- Yahoo
Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
WILMINGTON, Del., June 20, 2025--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib cream (Opzelura®), a topical Janus kinase (JAK) inhibitor, for the treatment of children 2-11 years old with mild to moderate atopic dermatitis (AD). The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to September 19, 2025. The FDA extended the PDUFA action date to allow time to review additional chemistry, manufacturing and controls (CMC) data on the 0.75% strength submitted by Incyte in response to a recent FDA information request. "Atopic dermatitis (AD) is a chronic immune-mediated skin condition that can be difficult to manage, particularly for the millions of children in the U.S. affected by AD," said Steven Stein, M.D., Chief Medical Officer, Incyte. "We are confident in the potential of ruxolitinib cream to become an important non-steroidal, topical treatment option for pediatric patients with atopic dermatitis and we will continue to work closely with the FDA to ensure the Agency has all of the information needed to complete its review." The sNDA submission for ruxolitinib cream in pediatric AD was based on data from the Phase 3 TRuE-AD3 study, which evaluated the safety and efficacy of ruxolitinib cream in children (age ≥2 to <12 years) with AD. The TRuE-AD3 study met its primary endpoint with significantly more patients treated with Opzelura achieving Investigator's Global Assessment-treatment success (IGA-TS), a measure of treatment efficacy, than patients treated with vehicle control (non-medicated cream). In addition, a secondary endpoint of patients demonstrating at least a 75% improvement in the Eczema Area and Severity Index (EASI75) at Week 8 was also achieved. The overall safety profile of Opzelura in the TRuE-AD3 trial was consistent with previous data, and no new safety signals were observed. No serious infections, major adverse cardiovascular events (MACE), malignancies or thromboses were reported during the 8-week vehicle-controlled period. The most common treatment-related adverse event among patients treated with Opzelura was application site pain (2.7% vs 0% in vehicle arm). These events were mild and did not lead to treatment interruption. About Opzelura® (ruxolitinib) Cream Opzelura (ruxolitinib) cream, a novel cream formulation of Incyte's selective JAK1/JAK2 inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older, is the first and only treatment for repigmentation approved for use in the United States. Opzelura is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants, such as azathioprine or cyclosporine, is not recommended. In Europe, Opzelura® (ruxolitinib) cream 15mg/g is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States as Opzelura. Opzelura and the Opzelura logo are registered trademarks of Incyte. IMPORTANT SAFETY INFORMATION OPZELURA is for use on the skin only. Do not use OPZELURA in your eyes, mouth, or vagina. OPZELURA may cause serious side effects, including: Serious Infections: OPZELURA contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while taking OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA. OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA. Increased risk of death due to any reason (all causes): Increased risk of death has happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking a medicine in the class of medicines called JAK inhibitors by mouth. Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers have happened in people taking a medicine in the class of medicines called JAK inhibitors by mouth. People taking JAK inhibitors by mouth have a higher risk of certain cancers including lymphoma and lung cancer, especially if they are a current or past smoker. Some people have had skin cancers while using OPZELURA. Your healthcare provider will regularly check your skin during your treatment with OPZELURA. Limit the amount of time you spend in the sunlight. Wear protective clothing when you are in the sun and use a broad-spectrum sunscreen. Increased risk of major cardiovascular events: Increased risk of major cardiovascular events such as heart attack, stroke, or death have happened in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and taking a medicine in the class of medicines called JAK inhibitors by mouth, especially in current or past smokers. Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening. Blood clots in the vein of the legs (deep vein thrombosis, DVT) and lungs (pulmonary embolism, PE) have happened more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a medicine in the class of medicines called JAK inhibitors by mouth. Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia). If needed, your healthcare provider will do a blood test to check your blood cell counts during your treatment with OPZELURA and may stop your treatment if signs or symptoms of low blood cell counts happen. Cholesterol increases: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides. Before starting OPZELURA, tell your healthcare provider if you: have an infection, are being treated for one, or have had an infection that does not go away or keeps coming back have diabetes, chronic lung disease, HIV, or a weak immune system have TB or have been in close contact with someone with TB have had shingles (herpes zoster) have or have had hepatitis B or C live, have lived in, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or become more severe if you use OPZELURA. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common. think you have an infection or have symptoms of an infection such as: fever, sweating, or chills, muscle aches, cough or shortness of breath, blood in your phlegm, weight loss, warm, red, or painful skin or sores on your body, diarrhea or stomach pain, burning when you urinate or urinating more often than usual, feeling very tired have ever had any type of cancer, or are a current or past smoker have had a heart attack, other heart problems, or a stroke have had blood clots in the veins of your legs or lungs in the past have high cholesterol or triglycerides have or have had low white or red blood cell counts are pregnant or plan to become pregnant. It is not known if OPZELURA will harm your unborn baby. There is a pregnancy exposure registry for individuals who use OPZELURA during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become exposed to OPZELURA during pregnancy, you and your healthcare provider should report exposure to Incyte Corporation at 1-855-463-3463 or are breastfeeding or plan to breastfeed. It is not known if OPZELURA passes into your breast milk. Do not breastfeed during treatment with OPZELURA and for about 4 weeks after the last dose. After starting OPZELURA: Call your healthcare provider right away if you have any symptoms of an infection. OPZELURA can make you more likely to get infections or make worse any infections that you have. Get emergency help right away if you have any symptoms of a heart attack or stroke while using OPZELURA, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw pain or discomfort in your arms, back, neck, jaw, or stomach shortness of breath with or without chest discomfort breaking out in a cold sweat nausea or vomiting feeling lightheaded weakness in one part or on one side of your body slurred speech Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with OPZELURA, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, or shortness of breath or difficulty breathing. Tell your healthcare provider right away if you develop or have worsening of any symptoms of low blood cell counts, such as: unusual bleeding, bruising, tiredness, shortness of breath, or fever. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. The most common side effects of OPZELURA in people treated for atopic dermatitis include: common cold (nasopharyngitis), diarrhea, bronchitis, ear infection, increase in a type of white blood cell (eosinophil) count, hives, inflamed hair pores (folliculitis), swelling of the tonsils (tonsillitis), and runny nose (rhinorrhea). The most common side effects of OPZELURA in people treated for nonsegmental vitiligo include: acne at the application site, itching at the application site, common cold (nasopharyngitis), headache, urinary tract infection, redness at the application site, and fever. These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463. Please see the Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA. INDICATIONS AND USAGE OPZELURA is a prescription medicine used on the skin (topical) for: short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis) in non-immunocompromised adults and children 12 years of age and older whose disease is not well controlled with topical prescription therapies or when those therapies are not recommended the treatment of a type of vitiligo called nonsegmental vitiligo in adults and children 12 years of age and older The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended. It is not known if OPZELURA is safe and effective in children less than 12 years of age with atopic dermatitis or nonsegmental vitiligo. About Incyte Dermatology Incyte's science-first approach and expertise in immunology has formed the foundation of the company. Today, we are building on this legacy as we discover and develop innovative dermatology treatments to bring solutions to patients in need. We strive to identify and develop therapies to modulate immune pathways driving uncontrolled inflammation. Specifically, our efforts in dermatology are focused on a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo, hidradenitis suppurativa, lichen sclerosus, and prurigo nodularis. To learn more, visit the Dermatology section of About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential for ruxolitinib cream to provide a successful treatment option for pediatric patients with AD; Incyte's plans to work with FDA; and Incyte's expectations with regard to the PDUFA date for its sNDA and regulatory approval, contain predictions, estimates, and other forward-looking statements. These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA and other regulatory agencies; the efficacy or safety of our products; the acceptance of our products in the marketplace; market competition; unexpected variations in the demand for our products and the products of our collaboration partners; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for our products; sales, marketing, manufacturing, and distribution requirements, including our ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional new products that become approved; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended March 31, 2025. We disclaim any intent or obligation to update these forward-looking statements. View source version on Contacts Media media@ Investors ir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
